Galectin Therapeutics Stock Technical Analysis
| GALT Stock | USD 2.10 -0.01 -0.47% |
As of the 9th of May, Galectin Therapeutics is valued at 2.10 per share. Indicator levels currently stand at Standard Deviation of 4.82, market risk adjusted performance of 0.3622, and Risk Adjusted Performance of -0.06. Historical price dispersion and volume trends are incorporated into the evaluation. Values are analyzed in relation to historical volatility thresholds.
Galectin Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Galectin, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to GalectinGalectin |
Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 11.0 | Hold | 1 | Odds |
Analyst recommendations for Galectin Therapeutics are summarized from various research providers. The average consensus rating provides a summary measure of analyst sentiment for Galectin Therapeutics. Coverage by multiple analysts provides a broader perspective on Galectin Therapeutics's valuation trajectory. Changes in analyst price targets for Galectin can be as informative as the ratings themselves. Divergences in Galectin price targets reflect differences in assumptions about growth, margins, and discount rates. Analyst coverage depth and direction are both valuable signals for Galectin investors.
Galectin Therapeutics's market price can diverge from book value, the accounting figure shown on Galectin's balance sheet. Galectin Therapeutics' market capitalization is 138.9 million. At P/B 207.7, Galectin Therapeutics trades at a significant premium to book value. Enterprise value (TTM) stands at 266.36 million. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value.
Value and price for Galectin Therapeutics are related but not identical, and they can diverge across cycles. For Galectin Therapeutics, key inputs include a P/B ratio of 207.7, and ROE of 23.0%.
What-If Analysis
What-if analysis for Galectin Therapeutics is essentially a historical sensitivity test that shows how changes in the investment horizon could have altered realized return, drawdown, and timing outcomes. In practice, this review provides context for deciding whether Galectin Therapeutics' historical reward profile was stable enough to support the current thesis.
| 02/08/2026 |
| 05/09/2026 |
Opening a 0.00 position in Galectin Therapeutics on February 8, 2026 and holding to today would record 0.00 in aggregate return. The net result is a 0.0% return on investment in Galectin Therapeutics in aggregate over the 90 day window. Galectin Therapeutics is often compared with DiaMedica Therapeutics, Design Therapeutics, Rocket Pharmaceuticals, Aura Biosciences, Alpha Tau, EnGene Holdings, and LB Pharmaceuticals based on sector and business overlap. Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of thera... More
Momentum Range Indicators for Galectin Therapeutics Overview
Directional momentum for Galectin Therapeutics is captured through indicators that track upside and downside price ranges. Price position within the recent range indicates whether momentum favors continuation or reversal.
| Information Ratio | -0.07 | |||
| Maximum Drawdown | 23.01 | |||
| Value At Risk | -8.92 | |||
| Potential Upside | 8.33 |
Galectin Therapeutics Market Risk Indicators Snapshot
Market risk indicators summarize volatility and return dispersion for Galectin Therapeutics. Maximum drawdown and recovery time capture the worst-case loss profile and how quickly the price rebounds.| Risk Adjusted Performance | -0.06 | |||
| Jensen Alpha | -0.33 | |||
| Total Risk Alpha | -0.32 | |||
| Treynor Ratio | 0.3522 |
Statistical evidence for mean reversion in Galectin Therapeutics' appears through its tendency to revert after extreme valuations. Under mean reversion theory, Galectin Therapeutics' price extremes are viewed as temporary dislocations that may self-correct. Mean reversion in Galectin Therapeutics' is often observed around historical valuation multiples. Historical data for Galectin Therapeutics shows that extreme valuations have tended to normalize over multi-year periods.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.06 | |||
| Market Risk Adjusted Performance | 0.3622 | |||
| Mean Deviation | 3.68 | |||
| Coefficient Of Variation | -1,516 | |||
| Standard Deviation | 4.82 | |||
| Variance | 23.28 | |||
| Information Ratio | -0.07 | |||
| Jensen Alpha | -0.33 | |||
| Total Risk Alpha | -0.32 | |||
| Treynor Ratio | 0.3522 | |||
| Maximum Drawdown | 23.01 | |||
| Value At Risk | -8.92 | |||
| Potential Upside | 8.33 | |||
| Skewness | -0.36 | |||
| Kurtosis | 0.6455 |
Galectin Therapeutics Backtested Returns
Galectin Therapeutics demonstrates an unstable price behavior under current market conditions. It has a Sharpe Ratio of -0.0634, evidencing negative risk-calibrated returns. We identified twenty-three technical indicators influencing the company's volatility profile. Please assess metrics such as standard deviation of 4.82, market risk-adjusted performance of 0.3622, and risk-adjusted performance of -0.06 to confirm statistical stability. The company owns a beta of -0.93, which implies generally lower market sensitivity than the broad market. As the market becomes more bullish, returns on owning Galectin Therapeutics tend to decrease slowly. On the other hand, during market turmoil, Galectin Therapeutics tends to outperform it slightly. At this point, Galectin Therapeutics has a negative expected return of -0.3%.
Auto-correlation | -0.41 |
Modest reverse predictability
Galectin Therapeutics shows modest reverse predictability when comparing price series from 8th of February 2026 to 25th of March 2026 against from 25th of March 2026 to 9th of May 2026. A strong serial relationship would imply that Galectin Therapeutics's recent trajectory contains information about its near-term direction. With a serial correlation of -0.41, just about 41.0% of Galectin Therapeutics's price variation is attributable to patterns in preceding intervals. Given that Galectin Therapeutics has negative autocorrelation for the selected time horizon, market participants may evaluate potential contrarian price behavior over comparable future intervals.
| Correlation Coefficient | -0.41 | |
| Spearman Rank Test | -0.31 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Technical signals for Galectin Therapeutics are derived from price and volume activity. The model references indicators tied to price trends and momentum.
Technical Analysis
This analysis covers thirty-seven data points across the selected time horizon. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Galectin Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Technical Analysis Methodology & Indicators
Technical analysis of Galectin Therapeutics evaluates price structure, momentum, and volatility clustering. Range expansion increases sensitivity to execution and spread conditions. Galectin Therapeutics has a market cap of 138.9 million, ROE of -37.28%.
Galectin Therapeutics inputs come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board
Technical Indicators
A technical review of Galectin Therapeutics can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. A disciplined technical workflow separates stronger setups from noisier price action.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.06 | |||
| Market Risk Adjusted Performance | 0.3622 | |||
| Mean Deviation | 3.68 | |||
| Coefficient Of Variation | -1,516 | |||
| Standard Deviation | 4.82 | |||
| Variance | 23.28 | |||
| Information Ratio | -0.07 | |||
| Jensen Alpha | -0.33 | |||
| Total Risk Alpha | -0.32 | |||
| Treynor Ratio | 0.3522 | |||
| Maximum Drawdown | 23.01 | |||
| Value At Risk | -8.92 | |||
| Potential Upside | 8.33 | |||
| Skewness | -0.36 | |||
| Kurtosis | 0.6455 |
May 9, 2026 Daily Trend Indicators
A technical review of Galectin Therapeutics can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. A disciplined technical workflow separates stronger setups from noisier price action.
| Accumulation Distribution | 5,845 | ||
| Daily Balance Of Power | -0.17 | ||
| Rate Of Daily Change | 1.00 | ||
| Day Median Price | 2.10 | ||
| Day Typical Price | 2.10 | ||
| Price Action Indicator | 0.00 |